among ORCEL LLC, as Assignor,Revenue Interests Assignment Agreement • February 12th, 2004 • Ortec International Inc • Biological products, (no disgnostic substances) • New York
FOURTH AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENTRevenue Interests Assignment Agreement • March 16th, 2006 • Orthovita Inc • Surgical & medical instruments & apparatus • New York
This FOURTH AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENT (this “Amendment”) is dated as of December 19, 2005, and is entered into by and among ORTHOVITA, INC., a Pennsylvania corporation (“Orthovita”), VITA SPECIAL PURPOSE CORP., a Delaware corporation and wholly-owned subsidiary of Orthovita (“Assignor”), and ROYALTY SECURITIZATION TRUST I, a Delaware statutory trust (“Assignee”).
FIFTH AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENTRevenue Interests Assignment Agreement • May 10th, 2007 • Orthovita Inc • Surgical & medical instruments & apparatus • New York
This FIFTH AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENT (this “Amendment”) is dated as of March 15, 2007, and is entered into by and among ORTHOVITA, INC., a Pennsylvania corporation (“Orthovita”), VITA SPECIAL PURPOSE CORP., a Delaware corporation and wholly-owned subsidiary of Orthovita (“Assignor”), and ROYALTY SECURITIZATION TRUST I, a Delaware statutory trust (“Assignee”).
THIRD AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENTRevenue Interests Assignment Agreement • May 9th, 2005 • Orthovita Inc • Surgical & medical instruments & apparatus • New York
This THIRD AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENT (this “Amendment”) is dated as of January , 2005, and is entered into by and among ORTHOVITA, INC., a Pennsylvania corporation (“Orthovita”), VITA SPECIAL PURPOSE CORP., a Delaware corporation and wholly-owned subsidiary of Orthovita (“Assignor”), and DEUTSCHE BANK TRUST COMPANY DELAWARE, not in its individual capacity, but solely as Owner Trustee of Royalty Securitization Trust I (“Assignee”).
FIRST AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENT AND TO GUARANTYRevenue Interests Assignment Agreement • November 29th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This FIRST AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENT AND TO GUARANTY (this “Amendment”) is dated as of November 28, 2006, and is entered into by and among King George Holdings Luxembourg IIA S.à r.l., a Luxembourg private limited company (together with its permitted successors and assigns, “King George”), Acorda Therapeutics, Inc., a Delaware corporation (“Acorda”), and Paul Royalty Fund II, L.P. (“Guarantor”).
REVENUE INTERESTS ASSIGNMENT AGREEMENT Dated as of July 21, 2006 and Restated as of August 18, 2006 between OSCIENT PHARMACEUTICALS CORPORATION, GUARDIAN II ACQUISITION CORPORATION and PAUL ROYALTY FUND HOLDINGS IIRevenue Interests Assignment Agreement • September 10th, 2008 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations • New York
This REVENUE INTERESTS ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of July 21, 2006 by and among Oscient Pharmaceuticals Corporation, a Massachusetts corporation (the “Company”), Guardian II Acquisition Corporation, a wholly-owned Delaware subsidiary of the Company, and Paul Royalty Fund Holdings II, a California general partnership (“PRF”).
REVENUE INTERESTS ASSIGNMENT AGREEMENTRevenue Interests Assignment Agreement • January 5th, 2006 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This REVENUE INTERESTS ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of December 23, 2005 by and between Acorda Therapeutics, Inc., a Delaware corporation (“Acorda”), and King George Holdings Luxembourg IIA S.à r.l., a Luxembourg private limited company (together with its permitted successors and assigns, “PRF”) and an Affiliate of Paul Royalty Fund II, L.P.
CONFIDENTIAL TREATMENT MATERIAL CONFIDENTIAL TREATMENT REQUESTED: Information for which confidential treatment has been requested is omitted and is noted with asterisks. An unredacted version of this document has been filed separately with the...Revenue Interests Assignment Agreement • May 10th, 2013 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This REVENUE INTERESTS ASSIGNMENT AGREEMENT, dated as of April 15, 2013 (this “Agreement”), is by and among Agenus Inc., a Delaware corporation (“Agenus”), Antigenics Inc., a Massachusetts corporation (“Agen MA”, and together with Agenus, the “Seller Parties” and each a “Seller Party”), Ingalls & Snyder Value Partners L.P. (“Ingalls”) and Arthur Koenig (“Koenig” and together with Ingalls, the “Buyers”). Capitalized terms used herein have the meanings assigned to them in Section 8.1.
REVENUE INTERESTS ASSIGNMENT AGREEMENT Dated as of July 21, 2006 and Restated as of August 18, 2006 between OSCIENT PHARMACEUTICALS CORPORATION, GUARDIAN II ACQUISITION CORPORATION and PAUL ROYALTY FUND HOLDINGS IIRevenue Interests Assignment Agreement • November 9th, 2006 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations • New York
This REVENUE INTERESTS ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of July 21, 2006 by and among Oscient Pharmaceuticals Corporation, a Massachusetts corporation (the “Company”), Guardian II Acquisition Corporation, a wholly-owned Delaware subsidiary of the Company, and Paul Royalty Fund Holdings II, a California general partnership (“PRF”).
SECOND AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENTRevenue Interests Assignment Agreement • March 16th, 2006 • Orthovita Inc • Surgical & medical instruments & apparatus • New York
This SECOND AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENT (this “Amendment”) is dated as of January 9, 2004, and is entered into by and among ORTHOVITA, INC., a Pennsylvania corporation (“Orthovita”), VITA SPECIAL PURPOSE CORP., a Delaware corporation and wholly-owned subsidiary of Orthovita (“Assignor”), and PAUL ROYALTY FUND, L.P., a Delaware limited partnership (formerly known as Paul Capital Royalty Acquisition Fund, L.P.) (“Assignee”).
THIRD AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENTRevenue Interests Assignment Agreement • March 16th, 2006 • Orthovita Inc • Surgical & medical instruments & apparatus • New York
This THIRD AMENDMENT TO REVENUE INTERESTS ASSIGNMENT AGREEMENT (this “Amendment”) is dated as of February 1, 2005, and is entered into by and among ORTHOVITA, INC., a Pennsylvania corporation (“Orthovita”), VITA SPECIAL PURPOSE CORP., a Delaware corporation and wholly-owned subsidiary of Orthovita (“Assignor”), and DEUTSCHE BANK TRUST COMPANY DELAWARE, not in its individual capacity, but solely as Owner Trustee of Royalty Securitization Trust I (“Assignee”).
FIRST AMENDMENT TO THE REVENUE INTERESTS ASSIGNMENT AGREEMENTRevenue Interests Assignment Agreement • November 7th, 2008 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
This first amendment dated as of November 5, 2008 (the “First Amendment”) to the Revenue Interests Assignment Agreement, dated July 21, 2006 and restated August 18, 2006, is between and among, Oscient Pharmaceuticals Corporation, a Massachusetts corporation (the “Company”), Guardian II Acquisition Corporation, a wholly-owned Delaware subsidiary of the Company, and Paul Royalty Fund Holdings II, a California general partnership (“PRF”), (the “Agreement”).
